Menu Search
Equities

Medx Health Corp

MDXHF:PKC

Medx Health Corp

Actions
  • Price (USD)0.0008
  • Today's Change0.00 / 0.00%
  • Shares traded130.00
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Nov 13 2024 16:28 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

MedX Health Corp. is a medical device and software company. It develops and manufactures skin-related screening tools and phototherapy devices for pain relief and tissue repair. It focuses on skin health with its SIAscopy on DermSecure telemedicine platform, utilizing its SIAscopy technology. SIAscopy is a medical device technology that is used to scan skin for suspicious moles and lesions and, including DermSecure, its telemedicine software application, and phototherapeutic medical devices, which use light energy in lower-level laser and light-emitting diode to provide treatment of pain and tissue damage in the rehabilitation market. Its products SIAMETRICS, SIMSYS, and MoleMate include hand-held devices that use patented technology utilizing light and its remittance to view up to two millimeters beneath suspicious moles and lesions in a pain free, non-invasive manner. Its SIAscopy on DermSecure telemedicine platform enables the Web-based operation of its SIAscopy scanning technology.

  • Revenue in CAD (TTM)388.64k
  • Net income in CAD-3.82m
  • Incorporated1999
  • Employees--
  • Location
    Medx Health Corp1495 Bonhill Road, Unit # 1 MississaugaMISSISSAUGA L5T 1M2CanadaCAN
  • Phone+1 (905) 670-4428
  • Fax+1 (905) 670-4749
  • Websitehttps://medxhealth.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.